Sofinnova Partners and New Enterprise Associates have co-led an oversubscribed series A round for Polyneuron Pharmaceuticals, spun out of University of Basel.

Goethe University Frankfurt has spun out Vivlion to commercialise a library of the human genome that could drive the development of more Crispr therapies.

An industrial biotech initiative co-led by University of Strathclyde has received UK government funding to prepare an application to the UKRI’s competitive Strength in Places program.

Sana has emerged with funding from investors including F-Prime Capital, Arch and Flagship Pioneering to develop genetically modified hypoimmogenic stem cells.

Hookipa Pharma, a Boehringer Ingelheim, Takeda and Gilead-backed infectious disease and cancer drug developer, has filed for an $86.3m IPO.

The firm posted its half-year results for the period ending December 2018, registering an 83% year-on-year rise in turnover and a 43% gain in the fair value of its portfolio.

Roche Venture Fund was among the existing investors that helped supply $50m for Arch Oncology, the cancer drug developer formerly known as Tioma.

The Mitsui-backed glucose monitoring technology provider will use the series E proceeds to fund the commercialisation of its device in the US.

The university will benefit from a hub to house its AI and biomedical research in addition to co-working space and a think-tank targeting the ethics of emerging technologies.

NetScientific has exited its loss-making portfolio companies Vortex and Wanda after originally deciding to close the two medical diagnostics ventures last week.